KIF11和KIF14是子宫内膜样癌患者一种新的潜在预后生物标志物。

KIF11 and KIF14 Are a Novel Potential Prognostic Biomarker in Patients with Endometrioid Carcinoma.

作者信息

Antosik Paulina, Durślewicz Justyna, Smolińska-Świtała Marta, Podemski Jonasz, Podemska Edyta, Neska-Długosz Izabela, Jóźwicki Jakub, Grzanka Dariusz

机构信息

Department of Clinical Pathomorphology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-094 Bydgoszcz, Poland.

出版信息

Cancers (Basel). 2025 Feb 26;17(5):804. doi: 10.3390/cancers17050804.

DOI:10.3390/cancers17050804

PMID:40075652

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11898751/

Abstract

The current study aimed to evaluate the function of KIF11 and KIF14 in endometroid cancer and assess their role as a prognostic biomarker and therapeutic target for treating endometroid cancer. Therefore, we immunohistochemically tested KIF11 and KIF14 proteins in tumoral and non-tumoral tissue sections from = 92 endometroid cancer patients with respect to major prognostic and predictive characteristics, as well as treatment outcome. We found that KIF11 protein levels were higher in tumor tissues as compared to normal tissues, whereas KIF14 protein levels were lower in cancer tissue. High KIF11 protein levels and low KIF14 protein levels were independent prognostic factors for poor OS. Furthermore, the expression profile of KIF11highKIF14low was associated with the worst OS, and it was superior to each single protein alone in predicting patient prognosis. In summary, individual and combined expression of KIF11 and KIF14 proteins may serve as potential prognostic biomarkers for endometroid cancer.

摘要

本研究旨在评估KIF11和KIF14在子宫内膜样癌中的功能，并评估它们作为子宫内膜样癌预后生物标志物和治疗靶点的作用。因此，我们对92例子宫内膜样癌患者的肿瘤组织和非肿瘤组织切片进行了免疫组织化学检测，检测KIF11和KIF14蛋白的主要预后和预测特征以及治疗结果。我们发现，与正常组织相比，肿瘤组织中KIF11蛋白水平更高，而癌组织中KIF14蛋白水平更低。高KIF11蛋白水平和低KIF14蛋白水平是总生存期较差的独立预后因素。此外，KIF11高KIF14低的表达谱与最差的总生存期相关，并且在预测患者预后方面优于单独的每种蛋白质。总之，KIF11和KIF14蛋白的单独和联合表达可能作为子宫内膜样癌的潜在预后生物标志物。